Loading...
ALXP
ALIKO
Market cap24mUSD
Oct 28, Last price  
1.40EUR
1D
5.26%
IPO
-67.74%
Name

Ikonisys SA

Chart & performance

D1W1MN
ALXP:ALIKO chart
P/E
—
P/S
15.98
EPS
—
Vol. 1Y
38.32%
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
1m
1,388,031
Net income
-4m
-4,203,451
CFO
-1m
-1,157,464

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in Paris, France, Ikonisys S.A. is a company specializing in cell-based diagnostics. It develops, produces, and commercializes medical diagnostic solutions for various cancers across the United States and Europe. Their core offering includes the Ikoniscope Robotic Microscope, which automates slide manipulation, scanning, and real-time image acquisition and analysis, thereby minimizing human error during diagnostic testing. The company provides a suite of specialized oncoFISH microscopy applications for cancer detection and characterization, such as oncoFISH bladder for analyzing urine samples, oncoFISH her2 for determining HER2 status in breast tissue biopsies, oncoFISH ALK for identifying rearrangements of the ALK gene, and oncoFISH PTEN for detecting PTEN gene deletions in prostate tissue biopsies. Ikonisys also offers tools for characterizing individual circulating tumor cells (CTCs) and analyzing circulating tumor DNA (ctDNA) to provide comprehensive tumor genotype information. Additionally, their Ikonisoft explorer software suite features dedicated FISH scanning applications: Ikonisoft explorer CS for cell suspensions on slides, and Ikonisoft explorer tissue for examining hybridized tissue sections. Finally, the IkoniWAN Gateway provides a secure, validated remote access solution for their Ikoniscope digital microscopy platforms.
IPO date
Jul 19, 2021
Employees
11
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
62 RUE DE CAUMARTIN
PARIS 75009
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FY
2025‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT